New hope for Tough-to-Treat nasopharyngeal cancer: ivonescimab trial launches
NCT ID NCT07565389
First seen May 05, 2026 · Last updated May 05, 2026
Summary
This study tests a drug called ivonescimab in 42 people with advanced nasopharyngeal cancer that has stopped responding to standard immunotherapy and chemotherapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants will receive the drug intravenously and be monitored for side effects and outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National University Cancer Institute, Singapore, National University Health System
Singapore, Singapore
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.